Inibitori della dipeptidil-peptidasi IV (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inibitori della dipeptidil-peptidasi IV" in Italian language version.

refsWebsite

Global rank Italian rank

12doi.org

2^nd place

7^th place

11nih.gov

4^th place

9^th place

5oadoi.org

799^th place

22^nd place

1sciencedirect.com

149^th place

298^th place

1fda.gov

447^th place

644^th place

1europa.eu

68^th place

57^th place

1web.archive.org

1^st place

1nasdaq.com

2,740^th place

3,855^th place

1diabetesjournals.org

low place

1pharmacypracticenews.com

low place

1bmj.com

1,226^th place

928^th place

1um.es

5,871^st place

low place

1nejm.org

2,374^th place

1,283^rd place

bmj.com

(EN) Devin Abrahami, Antonios Douros e Hui Yin, Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study, in BMJ, vol. 360, 21 marzo 2018, DOI:10.1136/bmj.k872. URL consultato il 27 novembre 2019.

diabetesjournals.org

care.diabetesjournals.org

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes, su care.diabetesjournals.org. URL consultato il 18 settembre 2015.

doi.org

dx.doi.org

Christopher H. S. McIntosh, Hans-Ulrich Demuth e J. Andrew Pospisilik, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?, in Regulatory Peptides, vol. 128, n. 2, 15 giugno 2005, pp. 159–165, DOI:10.1016/j.regpep.2004.06.001. URL consultato il 27 novembre 2019.
Margaret T Behme, John Dupré e Thomas J McDonald, Glucagon-like peptide 1 improved glycemic control in type 1 diabetes, in BMC Endocrine Disorders, vol. 3, 10 aprile 2003, p. 3, DOI:10.1186/1472-6823-3-3. URL consultato il 27 novembre 2019.
Joanne Bronson, Amelia Black, T. G., Murali Dhar, Bruce A. Ellsworth e J. Robert Merritt, Teneligliptin (Antidiabetic). To Market, To Market, in Annual Reports in Medicinal Chemistry, vol. 48, 2012, pp. 523–524, DOI:10.1016/b978-0-12-417150-3.00028-4.
Ihab M. Al-Masri, Mohammad K. Mohammad e Mutasem O. Tahaa, Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine, in Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 24, n. 5, 2009, pp. 1061–6, DOI:10.1080/14756360802610761, PMID 19640223.
McIntosh CH, Demuth HU, Pospisilik JA, Pederson R, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?, in Regul. Pept., vol. 128, n. 2, giugno 2005, pp. 159–65, DOI:10.1016/j.regpep.2004.06.001, PMID 15780435.
Behme MT, Dupré J, McDonald TJ, Glucagon-like peptide 1 improved glycemic control in type 1 diabetes, in BMC Endocr Disord, vol. 3, n. 1, aprile 2003, p. 3, DOI:10.1186/1472-6823-3-3, PMC 154101, PMID 12697069.
Francesco Salvo, Nicholas Moore e Mickael Arnaud, Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis, in The BMJ, vol. 353, 3 maggio 2016, DOI:10.1136/bmj.i2231. URL consultato il 27 novembre 2019.
Niranjan Kathe, Anuj Shah e Qayyim Said, DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case–Control Study, in Diabetes Therapy, vol. 9, n. 1, 2018-2, pp. 141–151, DOI:10.1007/s13300-017-0353-5. URL consultato il 27 novembre 2019.
Sean L. Zheng, Alistair J. Roddick e Rochan Aghar-Jaffar, Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes, in JAMA, vol. 319, n. 15, 17 aprile 2018, pp. 1580–1591, DOI:10.1001/jama.2018.3024. URL consultato il 27 novembre 2019.
(EN) Devin Abrahami, Antonios Douros e Hui Yin, Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study, in BMJ, vol. 360, 21 marzo 2018, DOI:10.1136/bmj.k872. URL consultato il 27 novembre 2019.
Masur K, Schwartz F, Entschladen F, Niggemann B, Zaenker KS, DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells, in Regul. Pept., vol. 137, n. 3, dicembre 2006, pp. 147–55, DOI:10.1016/j.regpep.2006.07.003, PMID 16908079.
Wesley UV, McGroarty M, Homoyouni A, Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway, in Cancer Res., vol. 65, n. 4, febbraio 2005, pp. 1325–34, DOI:10.1158/0008-5472.CAN-04-1852, PMID 15735018.

europa.eu

ema.europa.eu

Scheda linagliptin sul sito dell'Agenzia europea per i medicinali (PDF), su ema.europa.eu. URL consultato l'8 ottobre 2016.

fda.gov

FDA approves new treatment for Type 2 diabetes, su fda.gov, 2 maggio 2011. URL consultato il 15 aprile 2013.

nasdaq.com

Merck MARIZEV Once-Weekly DPP-4 Inhibitor For Type2 Diabetes Approved In Japan, su nasdaq.com, NASDAQ, 28 settembre 2015. URL consultato il 29 settembre 2015.

nejm.org

(EN) Amy G. Egan, Eberhard Blind, Kristina Dunder, Pieter A. de Graeff, B. Timothy Hummer, Todd Bourcier, Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment, su dx.doi.org, 26 febbraio 2014. URL consultato il 27 novembre 2019.

nih.gov

ncbi.nlm.nih.gov

Margaret T Behme, John Dupré e Thomas J McDonald, Glucagon-like peptide 1 improved glycemic control in type 1 diabetes, in BMC Endocrine Disorders, vol. 3, 10 aprile 2003, p. 3, DOI:10.1186/1472-6823-3-3. URL consultato il 27 novembre 2019.
Ihab M. Al-Masri, Mohammad K. Mohammad e Mutasem O. Tahaa, Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine, in Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 24, n. 5, 2009, pp. 1061–6, DOI:10.1080/14756360802610761, PMID 19640223.
McIntosh CH, Demuth HU, Pospisilik JA, Pederson R, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?, in Regul. Pept., vol. 128, n. 2, giugno 2005, pp. 159–65, DOI:10.1016/j.regpep.2004.06.001, PMID 15780435.
Behme MT, Dupré J, McDonald TJ, Glucagon-like peptide 1 improved glycemic control in type 1 diabetes, in BMC Endocr Disord, vol. 3, n. 1, aprile 2003, p. 3, DOI:10.1186/1472-6823-3-3, PMC 154101, PMID 12697069.
Francesco Salvo, Nicholas Moore e Mickael Arnaud, Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis, in The BMJ, vol. 353, 3 maggio 2016, DOI:10.1136/bmj.i2231. URL consultato il 27 novembre 2019.
Niranjan Kathe, Anuj Shah e Qayyim Said, DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case–Control Study, in Diabetes Therapy, vol. 9, n. 1, 2018-2, pp. 141–151, DOI:10.1007/s13300-017-0353-5. URL consultato il 27 novembre 2019.
Sean L. Zheng, Alistair J. Roddick e Rochan Aghar-Jaffar, Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes, in JAMA, vol. 319, n. 15, 17 aprile 2018, pp. 1580–1591, DOI:10.1001/jama.2018.3024. URL consultato il 27 novembre 2019.
Masur K, Schwartz F, Entschladen F, Niggemann B, Zaenker KS, DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells, in Regul. Pept., vol. 137, n. 3, dicembre 2006, pp. 147–55, DOI:10.1016/j.regpep.2006.07.003, PMID 16908079.
Pro B, Dang NH, CD26/dipeptidyl peptidase IV and its role in cancer, in Histol. Histopathol., vol. 19, n. 4, ottobre 2004, pp. 1345–51, PMID 15375776.
Wesley UV, McGroarty M, Homoyouni A, Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway, in Cancer Res., vol. 65, n. 4, febbraio 2005, pp. 1325–34, DOI:10.1158/0008-5472.CAN-04-1852, PMID 15735018.

pubmed.ncbi.nlm.nih.gov

(EN) Dupre J, Behme Mt, Hramiak Im, McFarlane P, Williamson Mp, Zabel P, Glucagon-like Peptide I Reduces Postprandial Glycemic Excursions in IDDM ^{[collegamento interrotto]}, su Diabetes, 1995-06. URL consultato il 27 novembre 2019.

oadoi.org

Joanne Bronson, Amelia Black, T. G., Murali Dhar, Bruce A. Ellsworth e J. Robert Merritt, Teneligliptin (Antidiabetic). To Market, To Market, in Annual Reports in Medicinal Chemistry, vol. 48, 2012, pp. 523–524, DOI:10.1016/b978-0-12-417150-3.00028-4.
Ihab M. Al-Masri, Mohammad K. Mohammad e Mutasem O. Tahaa, Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine, in Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 24, n. 5, 2009, pp. 1061–6, DOI:10.1080/14756360802610761, PMID 19640223.
McIntosh CH, Demuth HU, Pospisilik JA, Pederson R, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?, in Regul. Pept., vol. 128, n. 2, giugno 2005, pp. 159–65, DOI:10.1016/j.regpep.2004.06.001, PMID 15780435.
Masur K, Schwartz F, Entschladen F, Niggemann B, Zaenker KS, DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells, in Regul. Pept., vol. 137, n. 3, dicembre 2006, pp. 147–55, DOI:10.1016/j.regpep.2006.07.003, PMID 16908079.
Wesley UV, McGroarty M, Homoyouni A, Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway, in Cancer Res., vol. 65, n. 4, febbraio 2005, pp. 1325–34, DOI:10.1158/0008-5472.CAN-04-1852, PMID 15735018.

pharmacypracticenews.com

http://www.pharmacypracticenews.com/Policy/Article/04-16/Diabetes-Meds-Containing-Saxagliptin-and-Alogliptin-Linked-to-Increased-HF/35964/ses=ogst, su pharmacypracticenews.com. URL consultato il 27 novembre 2019.

sciencedirect.com

Christopher H. S. McIntosh, Hans-Ulrich Demuth e J. Andrew Pospisilik, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?, in Regulatory Peptides, vol. 128, n. 2, 15 giugno 2005, pp. 159–165, DOI:10.1016/j.regpep.2004.06.001. URL consultato il 27 novembre 2019.

um.es

hh.um.es

Pro B, Dang NH, CD26/dipeptidyl peptidase IV and its role in cancer, in Histol. Histopathol., vol. 19, n. 4, ottobre 2004, pp. 1345–51, PMID 15375776.

web.archive.org

LG Life Science, su lgls.com. URL consultato il 15 aprile 2013 (archiviato dall'url originale il 6 settembre 2013).